Back to News
Market Impact: 0.2
Leads Biolabs Doses First Patient In Phase 1b/2 Opamtistomig Trial In Colorectal Cancer
Source: Nasdaq
Healthcare & Biotech
Nanjing Leads Biolabs dosed the first patient in an open-label, multicenter Phase 1b/2 trial of Opamtistomig (LBL-024) in combination therapy for metastatic colorectal cancer. The announcement marks trial initiation; no efficacy or safety results were reported.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
mildly positive
Sentiment Score
0.15
More News
- Yields continue to rattle investors. These sectors are most at risk if rates stay elevated
- After years of U.S. export bans, China plans its own: 40 AI, chip and solar technologies could be restricted
- MapLight Therapeutics CMO Erin Foff sells $124,068 in stock
- William Blair initiates Revolution stock with outperform on RAS franchise
- Sickle cell gene therapies offer new hope, but access remains a major challenge
- Trump’s pharma holdings surged from $1.7 million in 2024 to $56.2 million as drugmakers gained Medicare exemptions, Democrats say